Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Nov 01, 2022 12:35pm
143 Views
Post# 35063531

RE:Stock moves

RE:Stock movesThe Oct. 31st meeting has come and gone.  The vote to allow Andrew Schutte to own 22.3% of Replicel was ratified without fanfare.  
Now that is in place it will be interesting to see if they are able to sell the remaining 5,500,000 shares with warrants after Andrew buys his 2,500,000.  This PP closes as announced on nov. 18th.

This hopefully will give the company adequate funding to get the Dermal injector to the "finish line" and pay the legal bills to the conclusion of the Shiseido Arbitration.

This is all good but what the hell is really happening with this company.   We get no updates on when the Dermal Injector will be submitted to the FDA for Approval and when will the Shiseido Arbitration conclude.  Also what is happening in Japan with the often  referenced partnership negotiations that have gone on endlessly for years ?  Can I also add Yofoto the mystery company that owns 5,357,900 shares of the company (12.53% presently).  What are they doing to fulfill the terms of their contract with Replicel ?

Possibly some sort of Update would be in order.



<< Previous
Bullboard Posts
Next >>